Dose Number as a Tool to Guide Lead Optimization for Orally Bioavailable Compounds in Drug Discovery-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dose Number as a Tool to Guide Lead Optimization for Orally Bioavailable Compounds in Drug Discovery

Published:2022-01-21 Issue:3 Volume:65 Page:1685-1694
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Wuelfing W. Peter¹,El Marrouni Abdellatif¹^ORCID,Lipert Maya P.²,Daublain Pierre³,Kesisoglou Filippos,Converso Antonella¹,Templeton Allen C.⁴

Affiliation:

1. Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States

2. AbbVie, Inc., 1401 Sheridan Road, North Chicago, Illinois 60064, United States

3. Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115 United States

4. Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065 United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c01687

Reference67 articles.

1. Can the pharmaceutical industry reduce attrition rates?

2. Diagnosing the decline in pharmaceutical R&D efficiency

3. An analysis of the attrition of drug candidates from four major pharmaceutical companies

4. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

5. Drug-like properties and the causes of poor solubility and poor permeability

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Amorphous Solubility Advantage: Theoretical Considerations, Experimental Methods, and Contemporary Relevance;Journal of Pharmaceutical Sciences;2024-09

2. Establishment of Dissolution Test Method for Multi-Components in Traditional Chinese Medicine Preparations Based on In Vitro–In Vivo Correlation;Pharmaceuticals;2024-08-14

3. Assessing and mitigating pH-mediated DDI risks in drug development – formulation approaches and clinical considerations;Drug Metabolism Reviews;2024-05-03

4. Invention of MK-7845, a SARS-CoV-2 3CL Protease Inhibitor Employing a Novel Difluorinated Glutamine Mimic;Journal of Medicinal Chemistry;2024-02-16

5. Exploring the structural-activity relationship of hexahydropyrazino[1,2-d]pyrido[3,2-b][1,4]oxazine derivatives as potent and orally-bioavailable PARP7 inhibitors;European Journal of Medicinal Chemistry;2023-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3